Compare TransMedics Group Inc (TMDX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Health Care Select Sector SPDR Fund — how do they compare? TransMedics Group Inc trades at $87.08 (market cap $3.10B), while Health Care Select Sector SPDR Fund trades at $168.42. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | XLV | |
|---|---|---|
Market Cap | $3.10B | — |
Sector | Technology | — |
52-Week High | $150.42 | $168.44 |
52-Week Low | $61.99 | $131.16 |
Enterprise Value | $3.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
XLV, the Health Care Select Sector SPDR ETF, trades at $168.44 with a neutral daily change. Technical indicators show a bullish trend from moving averages but oscillators are neutral, with the 6-day RSI at 86.78 suggesting overbought conditions. The fund's low 0.08% expense ratio and defensive healthcare sector exposure attract steady inflows amid market volatility, as highlighted by recent ETF flow reports.
The outlook for XLV is cautiously optimistic, supported by defensive demand and strong sector earnings. Key opportunities include diversification benefits and cost efficiency, while risks involve sector-specific regulatory pressures and broader economic sensitivity. Investors should weigh the ETF's stability against potential growth limitations in a concentrated portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
